JPH0639374B2 - Effervescent glycerin suppository - Google Patents

Effervescent glycerin suppository

Info

Publication number
JPH0639374B2
JPH0639374B2 JP59081648A JP8164884A JPH0639374B2 JP H0639374 B2 JPH0639374 B2 JP H0639374B2 JP 59081648 A JP59081648 A JP 59081648A JP 8164884 A JP8164884 A JP 8164884A JP H0639374 B2 JPH0639374 B2 JP H0639374B2
Authority
JP
Japan
Prior art keywords
glycerin
acid
suppository
carbonate
effervescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59081648A
Other languages
Japanese (ja)
Other versions
JPS60224614A (en
Inventor
健次 原
泰輝 江口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP59081648A priority Critical patent/JPH0639374B2/en
Publication of JPS60224614A publication Critical patent/JPS60224614A/en
Publication of JPH0639374B2 publication Critical patent/JPH0639374B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 本発明は発泡性グリセリン坐剤に関し、更に詳しくは、
炭酸塩及び/又は重炭酸塩、酸並びにグリセリンを含有
する、特に便秘治療に有効な発泡性グリセリン坐剤に関
する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to effervescent glycerin suppositories, and more specifically,
It relates to an effervescent glycerin suppository containing carbonate and / or bicarbonate, an acid and glycerin, which is particularly effective for treating constipation.

近年、食生活の変化やストレス社会の影響で、いわゆる
便秘症状を有する者は、増加する傾向にある。便秘の中
で最も多い弛緩性便秘は、大腸の運動機能の減弱のほか
に腸管や排便に関与する腹筋、内・外肛門括約筋、横隔
膜の筋力低下などが複雑に関連しており、老人、長期臥
床者、運動不足、無力体質者などにみられることが多
い。更に、便秘症状を有する者は消化器症状以外にもめ
まい、肩こり、頭重、頭痛易汗、のぼせ、動悸などの全
身的な症状を伴なうことも多く社会的に問題になつてい
る。
In recent years, the number of people who have so-called constipation symptoms tends to increase due to changes in eating habits and the effects of a stressful society. Inflammatory constipation, which is the most common type of constipation, is associated with complicated weakness of the motor function of the large intestine and weakness of the abdominal muscles, internal and external anal sphincter muscles, and diaphragm that are involved in the intestinal tract and defecation. It is often found in bedridden people, lack of exercise, and helplessness. In addition to digestive symptoms, people who have constipation symptoms are often socially associated with general symptoms such as dizziness, stiff neck, heavy head, easy sweating of headache, hot flashes, and palpitations.

現在、市販されている便秘薬の主流は刺激性下剤といわ
れるもので、化学合成物、漢方系などのタイプがある
が、腹痛や効きすぎによる下痢などの副作用があるほか
習慣性が伴うものが少なくない。また、最も一般的にグ
リセリン製剤が使用されているが、液状のものは10〜
20ml使用しなければ効果が得られず、使用中に直腸か
ら薬液がもれ出て下着を汚したり、あるいは直腸に注入
する場合に特殊な容器を用いなければならず、時として
容器による肛門周辺部の損傷を引き起す等の問題点があ
るため、その改善が望まれていた。その1つの解決法と
してグリセリン坐剤が開発されているが、坐剤という剤
型上一度に1〜3g程度しか投与出来ず充分効果が得ら
れないのが実状であつた。
Currently, the mainstream of constipation medications on the market are called stimulant laxatives, and there are types such as chemical compounds and Chinese herbs, but there are side effects such as abdominal pain and diarrhea due to over-effect, and those with habits. Not a few. Most commonly, glycerin preparations are used.
If you do not use 20 ml, the effect will not be obtained, and you will have to use a special container if you want to stain the underwear by leaking the drug solution from the rectum during use or inject it into the rectum, sometimes around the anus with a container Since there are problems such as causing damage to parts, improvements have been desired. Glycerin suppositories have been developed as one of the solutions, but the fact is that suppositories can be administered only at 1 to 3 g at a time and the effect cannot be sufficiently obtained.

本発明者は、斯かる実状に鑑み鋭意検討した結果、直腸
膨大部及び下部の蠕動運動に著しい影響を与える炭酸ガ
スとグリセリンとを併用することにより、従来のグリセ
リン坐剤に比べ便秘治療に極めて顕著な効果を奏する坐
剤が得られることを見出し、本発明を完成した。
The present inventor, as a result of diligent studies in view of such actual circumstances, by combining carbon dioxide and glycerin that significantly affect the peristalsis of the rectal ampulla and lower part, it is extremely useful for constipation treatment compared to conventional glycerin suppositories. It was found that a suppository having a remarkable effect can be obtained, and the present invention has been completed.

すなわち本発明の第一発明は、炭酸塩及び/又は重炭酸
塩、酸並びにグリセリンを含有する発泡性グリセリン坐
剤を提供するものである。
That is, the first invention of the present invention provides an effervescent glycerin suppository containing a carbonate and / or bicarbonate, an acid and glycerin.

本発明の発泡性グリセリン坐剤に使用する炭酸塩及び/
又は重炭酸塩としては、例えば炭酸水素ナトリウム、炭
酸ナトリウム、セスキ炭酸ナトリウム、炭酸カリウム、
炭酸水素カリウム、炭酸アンモニウム等が挙げられる
が、就中特に炭酸水素ナトリウム、炭酸ナトリウムが好
ましい。
Carbonate used in the effervescent glycerin suppository of the present invention and /
Or, as the bicarbonate, for example, sodium hydrogen carbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate,
Potassium hydrogen carbonate, ammonium carbonate and the like can be mentioned, but sodium hydrogen carbonate and sodium carbonate are particularly preferable.

また、酸としては、例えばクエン酸、酒石酸、リンゴ
酸、マロン酸、ピリドンカルボン酸、コハク酸、マレイ
ン酸、グルタミン酸、グルコノデルタラクトン、グルコ
ン酸、乳酸、フマル酸、リン酸、アジピン酸、クエン酸
ナトリウム、コハク酸ナトリウム、カリウムハイドロジ
オキシコハク酸、フマル酸ナトリウム、リン酸ナトリウ
ム、リン酸二水素ナトリウム、リン酸水素二ナトリウ
ム、スルフアミン酸等が挙げられるが、就中特にリン酸
二水素ナトリウムが好ましい。酸の含有量は、発泡性グ
リセリン坐剤中に存在する当該炭酸塩の重量に対して1
0〜300重量%、特に30〜150重量%が好まし
い。
Examples of the acid include citric acid, tartaric acid, malic acid, malonic acid, pyridonecarboxylic acid, succinic acid, maleic acid, glutamic acid, gluconodeltalactone, gluconic acid, lactic acid, fumaric acid, phosphoric acid, adipic acid, and citric acid. Sodium acid, sodium succinate, potassium hydrooxysuccinic acid, sodium fumarate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sulfamic acid, and the like, but especially sodium dihydrogen phosphate. Is preferred. The content of acid is 1 with respect to the weight of the carbonate present in the effervescent glycerin suppository.
0 to 300% by weight, particularly 30 to 150% by weight are preferred.

なお、これらの炭酸塩及び/又は重炭酸塩、並びに酸は
いずれも予め乾燥しておいたものを使用するのがより好
適である。
It is more preferable to use the carbonate and / or bicarbonate and the acid that have been dried in advance.

ところで、上記炭酸塩及び/又は重炭酸塩、酸並びにグ
リセリンを含有する本発明の発泡性グリセリン坐剤はそ
の効果としては優れたものであるが、炭酸塩及び/又は
重炭酸塩、並びに酸としてたとえ無水物を使用したとし
ても、僅かな水分の存在によつて両者が反応して炭酸ガ
スを発生するため、経日的には更に安定性の点で改善の
余地のあるものである。
By the way, the effervescent glycerin suppository of the present invention containing the above-mentioned carbonate and / or bicarbonate, acid and glycerin is excellent in its effect, but as a carbonate and / or bicarbonate and an acid, Even if an anhydride is used, both of them react with each other due to the presence of a slight amount of water to generate carbon dioxide, and therefore there is room for improvement in terms of stability over time.

そこで、本発明者は、斯かる安定性を改善すべく鋭意研
究を行なつた結果、安定化剤として酸化マグネシウム、
酸化カルシウム又はアルミン酸ナトリウムを配合すれば
経日的保存安定性のよい発泡性グリセリン坐剤が得られ
ることを見出し、本発明の第2発明を完成させた。
Therefore, the present inventor has conducted diligent research to improve such stability, resulting in magnesium oxide as a stabilizer,
It was found that an effervescent glycerin suppository having good storage stability over time can be obtained by adding calcium oxide or sodium aluminate, and completed the second invention of the present invention.

すなわち第2発明は、炭酸塩及び/又は重炭酸塩、酸、
グリセリン、並びに酸化マグネシウム、酸化カルシウム
及びアルミン酸ナトリウムよりなる群から選ばれた物質
を含有する発泡性グリセリン坐剤を提供するものであ
る。
That is, the second invention relates to a carbonate and / or a bicarbonate, an acid,
An effervescent glycerin suppository containing glycerin and a substance selected from the group consisting of magnesium oxide, calcium oxide and sodium aluminate.

酸化マグネシウム、酸化カルシウム又はアルミン酸ナト
リウムは、その全用量が当該炭酸塩及び/又は重炭酸
塩、並びに酸の混合物に対して0.5〜15重量%、特
に0.5〜10重量%となるように配合するのが好まし
い。配合量が0.1重量%未満では安定化効果が不充分
である。なお、安定化剤の粒度は、特に制限されない
が、1000μ以下が好ましく、特に500μ以下が好まし
い。
The total dose of magnesium oxide, calcium oxide or sodium aluminate amounts to 0.5 to 15% by weight, in particular 0.5 to 10% by weight, based on the carbonate and / or bicarbonate and the mixture of acids. It is preferable to mix them as follows. If the blending amount is less than 0.1% by weight, the stabilizing effect is insufficient. The particle size of the stabilizer is not particularly limited, but is preferably 1000 μm or less, and particularly preferably 500 μm or less.

また、本発明品において、炭酸塩及び/又は重炭酸塩、
酸及び/又は安定化剤の混合物は、グリセリンに対して
20〜90重量%、特に30〜80重量%配合するのが
好ましい。
In the product of the present invention, carbonate and / or bicarbonate,
The mixture of the acid and / or the stabilizer is preferably blended in an amount of 20 to 90% by weight, particularly 30 to 80% by weight, based on glycerin.

本発明の発泡性グリセリン坐剤は、炭酸塩及び/又は重
炭酸塩、酸及び/又は安定化剤を濃グリセリンとよく混
合してソフトゼラチンカプセルに充填する方法、あるい
は炭酸塩及び/又は重炭酸塩、酸及び/又は安定化剤
を、濃グリセリンと例えばステアリン酸、ステアリン酸
ナトリウム、高重合ポリエチレングリコール及び高重合
ポリプロピレングリコールよりなる群から選ばれた1種
又は2種以上との混合物とよく混合して坐剤鋳型により
製剤化する方法等により製造される。
The effervescent glycerin suppository of the present invention is prepared by thoroughly mixing a carbonate and / or bicarbonate, an acid and / or a stabilizer with concentrated glycerin and filling them into a soft gelatin capsule, or a carbonate and / or bicarbonate. A salt, an acid and / or a stabilizer are mixed well with a mixture of concentrated glycerin and one or more selected from the group consisting of stearic acid, sodium stearate, highly polymerized polyethylene glycol and highly polymerized polypropylene glycol. Then, the suppository mold is used to formulate.

更に本発明の発泡性グリセリン坐剤には、薬用石鹸、水
酸化ナトリウム、流動パラフイン、レシチン、界面活性
剤などを配合して効果を一層高めることもできる。
Further, the effervescent glycerin suppository of the present invention may be blended with medicated soap, sodium hydroxide, liquid paraffin, lecithin, surfactant and the like to further enhance the effect.

本発明の発泡性グリセリン坐剤は、炭酸ガスとグリセリ
ンの作用で大腸の蠕動運動を促進することによつて生理
的に排便促進作用を発揮するものであり、おだやかな自
然に近い便通が得られ、かつ、従来品と比較して少量の
薬剤で充分な効果があり、使用法が簡便なので、急性便
秘、慢性便秘、術後便秘のみならず、高令者、病床者、
妊産婦にも使用することができる。
The effervescent glycerin suppository of the present invention is one that exerts a physiological defecation promoting action by promoting peristaltic movement of the large intestine by the action of carbon dioxide and glycerin, and a gentle natural bowel movement can be obtained. In addition, it has sufficient effects with a small amount of drug compared to conventional products and is easy to use, so not only acute constipation, chronic constipation, postoperative constipation, but also elderly people, beds,
It can also be used by pregnant women.

次に実施例を挙げて説明する。Next, examples will be described.

実施例1 表1に示す組成の坐剤を製造した。Example 1 A suppository having the composition shown in Table 1 was produced.

すなわち、成分〜を45℃で充分融解・混合し、1g
宛坐剤鋳型を用いて製剤化した。
That is, the ingredients ~ are thoroughly melted and mixed at 45 ° C, and 1g
It was formulated using a suppository template.

得られた坐剤について、3日間便通のない者の直腸内に
挿入したとき、約15分後に便通が得られるために必要な
量を調べた。結果を表1に示す。
About the obtained suppository, when it was inserted into the rectum of a person who had no bowel movement for 3 days, the amount required to obtain bowel movement was examined after about 15 minutes. The results are shown in Table 1.

表1の結果から明らかなように、本発明の坐剤は、その
1gを用いることにより約15分後に3日間便通のない者
に便通を得ることができた。
As is clear from the results in Table 1, the use of 1 g of the suppository of the present invention made it possible to obtain a bowel movement in a person who had no bowel movement for 3 days after about 15 minutes.

また、NO.1の坐剤をアルミニウムをラミネートしたフィ
ルムで密閉包装し、温度40℃、湿度75%で6ケ月間保存
したところ、この包装品には全く異常は認められなかっ
た。これに対し、酸化マグネシウムを含まないNO.4の坐
剤は、同様の条件下で保存したところ、約2ケ月後に包
装容器が膨張し、また坐剤も使用不可能となった。
Further, when No. 1 suppository was hermetically packaged with a film laminated with aluminum and stored at a temperature of 40 ° C. and a humidity of 75% for 6 months, no abnormality was observed in this packaged product. On the other hand, the NO.4 suppository containing no magnesium oxide, when stored under the same conditions, the packaging container swelled after about two months, and the suppository became unusable.

実施例2 組成: 濃グリセリン 100重量部 炭酸ナトリウム 30 リン酸水素二ナトリウム 25 酸化カルシウム 1 〜を40℃でよく混合したのち、500mg宛ソフト
ゼラチンカプセルに充填した。本品1個を3日間便通の
ない者の直腸内に挿入したところ、約10分後に便通が得
られた。また本品をアルミニウムをラミネートしたフィ
ルムで密封包装し、温度40℃、湿度75%で6ケ月保
存したところ、この包装品には全く異常は認められなか
つた。本品は1回に2個使用する。
Example 2 Composition: Concentrated glycerin 100 parts by weight Sodium carbonate 30 Disodium hydrogen phosphate 25 Calcium oxide 1 to 1 were mixed well at 40 ° C., and then filled into 500 mg soft gelatin capsules. When this product was inserted into the rectum of a person who had no bowel movement for 3 days, a bowel movement was obtained after about 10 minutes. Further, when this product was hermetically packaged with a film laminated with aluminum and stored at a temperature of 40 ° C. and a humidity of 75% for 6 months, no abnormality was observed in this packaged product. Use two of this product at a time.

実施例3 組成: 濃グリセリン 100重量部 ステアリン酸ナトリウム7.5 水酸化ナトリウム 1.3 炭酸水素ナトリウム 35 クエン酸 30 アルミン酸ナトリウム 0.8 〜を40℃でよく混合し、1g宛坐剤鋳型を用いて
製剤化した。本品1個を4日間便通のない者の直腸内に
挿入したところ、約10分後に便通が得られた。
Example 3 Composition: Concentrated glycerin 100 parts by weight Sodium stearate 7.5 Sodium hydroxide 1.3 Sodium hydrogen carbonate 35 Citric acid 30 Sodium aluminate 0.8-Well well mixed at 40 ° C. Used for formulation. When this product was inserted into the rectum of a person who had no bowel movement for 4 days, a bowel movement was obtained after about 10 minutes.

また本品をアルミニウムをラミネートしたフイルムで密
封包装し、温度40℃、湿度75%で6ケ月間保存した
ところ、この包装品には全く異常は認められなかつた。
Further, when this product was hermetically packaged in a film laminated with aluminum and stored at a temperature of 40 ° C. and a humidity of 75% for 6 months, no abnormalities were observed in this packaged product.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 33/42 8314−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location A61K 33/42 8314-4C

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】炭酸塩及び/又は重炭酸塩、酸並びにグリ
セリンを含有する発泡性グリセリン坐剤。
1. An effervescent glycerin suppository containing a carbonate and / or bicarbonate, an acid and glycerin.
【請求項2】炭酸塩及び/又は重炭酸塩、酸、グリセリ
ン、並びにそれ自体で緩下剤効果を奏さない量の酸化マ
グネシウム、酸化カルシウム及びアルミン酸ナトリウム
よりなる群から選ばれた物質を含有する発泡性グリセリ
ン坐剤。
2. A foam containing carbonate and / or bicarbonate, an acid, glycerin, and a substance selected from the group consisting of magnesium oxide, calcium oxide and sodium aluminate in an amount that does not exert a laxative effect on its own. Glycerin suppository.
JP59081648A 1984-04-23 1984-04-23 Effervescent glycerin suppository Expired - Lifetime JPH0639374B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59081648A JPH0639374B2 (en) 1984-04-23 1984-04-23 Effervescent glycerin suppository

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59081648A JPH0639374B2 (en) 1984-04-23 1984-04-23 Effervescent glycerin suppository

Publications (2)

Publication Number Publication Date
JPS60224614A JPS60224614A (en) 1985-11-09
JPH0639374B2 true JPH0639374B2 (en) 1994-05-25

Family

ID=13752155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59081648A Expired - Lifetime JPH0639374B2 (en) 1984-04-23 1984-04-23 Effervescent glycerin suppository

Country Status (1)

Country Link
JP (1) JPH0639374B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610266A1 (en) * 1986-03-26 1987-10-01 Technica Entwicklung Product for external cosmetic care or medical treatment
FR2746643B1 (en) * 1996-04-01 1998-06-12 Techni Pharma NOVEL LAXATIVE COMPOSITIONS AND THEIR MANUFACTURING PROCESS
JP3509563B2 (en) 1998-03-10 2004-03-22 トヨタ自動車株式会社 Internal combustion engine having a combustion heater
JP4346311B2 (en) * 2001-04-27 2009-10-21 京都薬品工業株式会社 How to store effervescent suppositories
DE10221089A1 (en) * 2002-05-11 2003-11-27 Ferdinand Schmitt Suppositories containing material forming gas and/or foam in vivo, give even distribution of active agent, e.g. activated carbon or drug, over large area of the lower intestines
WO2012092990A2 (en) * 2011-01-05 2012-07-12 Udo Wenske Medical product for improving the ability of a mammal to conceive
IT201700054380A1 (en) * 2017-05-19 2018-11-19 Aboca Spa Societa Agricola COMPOSITIONS CONTAINING CARBON DIOXIDE RELEASE SYSTEMS OBTAINED FROM VEGETABLE JUICES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS428250Y1 (en) * 1964-02-29 1967-04-27
JPS60266B2 (en) * 1982-05-24 1985-01-07 本田技研工業株式会社 Motorcycle step device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
第十改正日本薬局方解説書A・B・C1981C−664〜C−667、C−805〜C−809(株)廣川書店

Also Published As

Publication number Publication date
JPS60224614A (en) 1985-11-09

Similar Documents

Publication Publication Date Title
EP0349235B1 (en) Niacin and guar-gum containing composition
JP5276435B2 (en) Polyethylene glycol colon laxative composition
US4393071A (en) Method of treating gastric, mammary, lung and uterus tumors
US20070298100A1 (en) Compressed Pharmaceutical Compositions Comprising Peg and Electrolytes
JPS60222427A (en) Foa mable anhydrous composition
CA2241445C (en) Non-aqueous colonic purgative formulations
JPS62123133A (en) Preparation of dry carrier for controlled long life blended medicine and dry carrier thereby
JPH0639374B2 (en) Effervescent glycerin suppository
JPS62298530A (en) Pharmaceutical composition for suppository
US4985257A (en) Hemorrhoidal treatment and composition
JP2010163428A (en) Disintegrating tablet
JP2002255852A (en) Spray preparation for stomatitis
Geiling The posterior hypophysis
JPH03284620A (en) Composition for cleaning intestine
Necheles et al. Peptic Ulcer in Man Part 4. A New Antacid Made To Meet Requirements Of Antacid Therapy, Chemical And Laboratory Work
US3077435A (en) Therapeutic composition comprising 4-(2-dimethylaminoethoxy)-4-(3, 4, 5-trimethoxybenzoyl)-benzylamine and betapyridylcarbinol
Winslow Veterinary materia medica and therapeutics
JPS6165822A (en) Agent for vaginal application
US2766174A (en) Self-sterilizing antihistaminic solution of 3-(p-chlorophenyl)-3-(2-pyridyl)-n, n-dimethyl propylamine
KR20230140488A (en) A composition for bowel cleansing
A non-proprietary JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.
SWARTZ Drug Formus: NuLYTELY (PEG 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution)
US3172806A (en) Pharmaceutical composition for treating nausea and vomiting
DE2342214A1 (en) REMEDIES
CN1326788A (en) Supersonic development agent for gastrointestinal tract and its preparing method